Matt Martin, PharmD, BCSCP, PCCA Director of Clinical Services, reviews USP 797 revisions and impacts on compounding pharmacies in the third of a four-part series.

Matt Martin writes to help compounding pharmacies navigate the Food and Drug Administration’s (FDA’s) recently finalized guidance document Insanitary Conditions at Compounding Facilities.